Preclinical Assessment of [

Animals Cell Death Gallium Radioisotopes Humans Ligands Male Positron Emission Tomography Computed Tomography Positron-Emission Tomography / methods Radiometry Radiopharmaceuticals / pharmacology Rats Rats, Inbred Lew Tissue Distribution
Cell death GSAO apoptosis gallium- 68 positron emission tomography computed tomography positron-emission tomography

Journal

Current radiopharmaceuticals
ISSN: 1874-4729
Titre abrégé: Curr Radiopharm
Pays: United Arab Emirates
ID NLM: 101468718

Informations de publication

Date de publication:
2022
Historique:
received: 02 08 2021
revised: 28 09 2021
accepted: 15 10 2021
pubmed: 24 11 2021
medline: 29 7 2022
entrez: 23 11 2021
Statut: ppublish

Résumé

4-(N-(S-glutathionylacetyl)amino) phenylarsonous acid (GSAO) when conjugated with a bifunctional chelator 2,2'-(7-(1-carboxy-4-((2,5-dioxopyrrolidin-1-yl)oxy)-4- oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic acid (NODAGA) (hereafter referred to as Cell Death Indicator [CDI]), enters dead and dying cells and binds to 90kDa heat shock proteins (hsp90). This study assesses stability, biodistribution, imaging, and radiation dosimetry of [68Ga]- Ga-CDI for positron emission tomography (PET). Preparation of [ Radiochemical purity of [ [

Sections du résumé

BACKGROUND BACKGROUND
4-(N-(S-glutathionylacetyl)amino) phenylarsonous acid (GSAO) when conjugated with a bifunctional chelator 2,2'-(7-(1-carboxy-4-((2,5-dioxopyrrolidin-1-yl)oxy)-4- oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic acid (NODAGA) (hereafter referred to as Cell Death Indicator [CDI]), enters dead and dying cells and binds to 90kDa heat shock proteins (hsp90).
OBJECTIVE OBJECTIVE
This study assesses stability, biodistribution, imaging, and radiation dosimetry of [68Ga]- Ga-CDI for positron emission tomography (PET).
METHODS METHODS
Preparation of [
RESULTS RESULTS
Radiochemical purity of [
CONCLUSION CONCLUSIONS
[

Identifiants

DOI: 10.2174/1874471014666211122100646 PMID: 34809552
pubmed: 34809552
pii: CRP-EPUB-118978
doi: 10.2174/1874471014666211122100646
doi:

Substances chimiques

Gallium Radioisotopes 0
Ligands 0
Radiopharmaceuticals 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

184-193

Subventions

Organisme : National Health and Medical Research Council of Australia
ID : 1110219, 1143398, 1143400

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Ivan Ho Shon (IH)

Department of Nuclear Medicine and PET, Prince of Wales Hospital, Randwick, Sydney, NSW 2031, Australia.
The Centenary Institute, The University of Sydney, Camperdown, Sydney, NSW 2050, Australia.
Prince of Wales Clinical School, University of New South Wales, Sydney, Australia.

Divesh Kumar (D)

Department of Nuclear Medicine and PET, Fiona Stanley Hospital, Murdoch, WA, Australia.

Mark Schreuder (M)

The Centenary Institute, The University of Sydney, Camperdown, Sydney, NSW 2050, Australia.

Jennifer Guille (J)

Department of Nuclear Medicine and PET, Prince of Wales Hospital, Randwick, Sydney, NSW 2031, Australia.

John Doan (J)

Department of Nuclear Medicine and PET, Prince of Wales Hospital, Randwick, Sydney, NSW 2031, Australia.
Biological Resource Imaging Laboratory, University of New South Wales, Sydney, Australia.

Chithra Sathikumar (C)

Department of Nuclear Medicine and PET, Liverpool Hospital, Liverpool, Sydney, NSW 2170, Australia.

Khang Van (K)

Department of Nuclear Medicine and PET, Liverpool Hospital, Liverpool, Sydney, NSW 2170, Australia.

Andrew Chicco (A)

Department of Medical Physics, Westmead Hospital, Sydney, NSW 2145, Australia.

Philip J Hogg (PJ)

The Centenary Institute, The University of Sydney, Camperdown, Sydney, NSW 2050, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Preclinical Assessment of [
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Preclinical Assessment of [
questionsmedicales.fr › Produits chimiques inorganiques › Métaux › Métaux lourds › Gallium › Isotopes du gallium › Radio-isotopes du gallium › Preclinical Assessment of [
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Preclinical Assessment of [
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Ligands › Preclinical Assessment of [
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Tomographie par émission de positons couplée à la tomodensitométrie › Preclinical Assessment of [
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Preclinical Assessment of [
questionsmedicales.fr › Techniques d'investigation › Radiométrie › Preclinical Assessment of [
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Indicateurs et réactifs › Radiopharmaceutiques › Preclinical Assessment of [
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Preclinical Assessment of [
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Lignées consanguines de rats › Rats de lignée LEW › Preclinical Assessment of [
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Pharmacocinétique › Distribution tissulaire › Preclinical Assessment of [